Keynote & Plenary Speakers

Get a sneak peek below at the exciting keynote lectures and plenary sessions that will be part of the IPVC 2024 scientific program.

All times below are in Edinburgh, UK Local Time – Greenwich Mean Time (GMT).

If you want to be the first to know all IPVC 2024 updates, sign up for our newsletter here.

Tuesday, November 12

OPENING KEYNOTE AND INTRODUCTION TO IPVC

• The role of respectful partnership in the delivery of global health goals, with particular reference to Scotland and Malawi.
  Heather Cubie

Wednesday, November 13

PLENARY SESSION 1: HPV- The Fundamentals

• HPV replication throughout the life cycle
  Alison McBride (USA)

• HPV from infection to cancer
  Karl Munger (USA)

• HPV signal transduction-a target for anti-virals
  Michelle Ozbun (USA)

PLENARY SESSION 2: Therapeutic cancer vaccines

• General concepts of cancer interception vaccines
  Olivera Finn

• Combination immunotherapy of HPV-induced cancers, including T cell induction by therapeutic vaccines
  Cornelis Melief
• Clinical trials and promising results to date of therapeutic vaccines (together with immunotherapeutic agents) for HPV-related head and neck and cervical cancers
  Katharine Price

Thursday, November 14

PLENARY SESSION 3: Rapid, low-cost HPV cervical screening technologies to meet elimination.

• Overview of current and emerging technologies for low-cost tests to meet elimination goals introducing the concept of WHO prequalification of assays
  Maribel Almonte

• Screening trials with treatment algorithms of care as one aspect of the elimination program in LMIC
  Rakiya Saidu

• Reaching the third target: Treatment for all.
  Hennie Botha

Friday, November 15

PLENARY SESSION 4: Implementation Science

• An overview of principles of implementation science research with an HPV lens
  Maria Fernandez
• Implementation science of cervical cancer prevention strategies in Nigeria
  Juliet Iwelunmor
• Use of implementation science to strengthen cervical cancer prevention in Argentina
  Silvina Arrossi

CLOSING PLENARY

• Vaccine Technology (preventative and therapeutic)
  Ian Frazer
• Will Australia be the first to eliminate cervical cancer?
  Suzanne Garland (Australia)

Tuesday, April 18	16:30-18:00 OPENING CEREMONY AND KEYNOTE LECTURE Comparing and Contrasting COVID-19 Control with HPV Control and Elimination Barney Graham, USA
Wednesday, April 19	11:00-12:30 PLENARY SESSION 1 One-dose HPV vaccination overview and a focus on the KENSHE data Ruanne Barnabas, USA New prophylactic HPV vaccines Richard Roden, USA Therapeutic vaccines in particular with clinical outcomes such as CIN 3 Mayumi Nakagawa, USA
Thursday, April 20	8:30-10:00 PLENARY SESSION 2 Lessons learned from other disease control programs such as HIV Helen Rees, South Africa What can we learn from the hepatitis B model in elimination of HPV-related diseases?  Mark Kane, USA Anal cancer control approaches Joel Palefsky, USA   16:40-18:10 PLENARY SESSION 3 Mastomys Coucha: a unique animal model for papillomavirus-induced skin carcinogenesis Frank Rosl, Germany Pros and cons of Beta HPVs as causative agents in skin cancer Denise Galloway, USA *Special Tribute to Massimo Tommasino on his work on Epidemiology and Biology of Beta Human Papillomavirus Types
Friday, April 21	11:45-13:15 PLENARY SESSION 4 Covid-19 effect on cervical screening Mona Saraiya, USA Re-invigorating efforts towards cervical cancer elimination: mitigating the impact of Covid-19 Karen Canfell, Australia What will it take (and how to) achieve cervical cancer elimination goal by 2030 with a perspective for low and middle income countries? Yin Ling Woo, Malaysia   16:00-17:15 CLOSING CEREMONY AND KEYNOTE LECTURE The future is now  Douglas Lowy, USA

Tuesday, November 16, 2021
15:30-17:15

Successful vaccines – what’s the secret?
Prof. Mark K. Slifka, USAWednesday, November 17, 2021
14:30-16:00

Public trust in vaccines 
Dr. Maya J. Goldenberg, Canada

Immunotherapy for HPV
Dr. Sjoerd van der Burg, Netherlands

Next-generation HPV vaccines integrating biology and engineering
Dr. Robert L. Garcea, USAThursday, November 18, 2021
10:00-11:30

Inequity in global access to health and justice
Dr. Gina Ogilvie. Canada

Global HPV vaccine supply & demand and the impact of the COVID-19 pandemic
Dr. Tania Cernuschi, Switzerland

Cervical cancer prevention and management as part of comprehensive sexual and reproductive health care for women in sub-Saharan Africa
Dr. Peter Jay Hotez, USAThursday, November 18, 2021
14:30-15:30

HNSCC development and progression: Avenues for therapeutic development 
Dr. Jennifer R. Grandis, USA

RRP: the paradigm for HPV immune evasion
Dr. Vincent R. Bonagura, USAFriday, November 19, 2021
10:30-11:30

Exploiting DNA damage repair by HPV
Prof. Laimonis A Laimins, USA

Vaginal and anal microbiome 
Prof. Adam Burgener, USAFriday, November 19, 2021
15:30-17:00

Research in HPV: past, present, and future
Dr. Eduardo Franco, CanadaScientific Program